Polymorph Drug Patents and Their Public Health Impact

Jaqueline Soares,Eduardo Guimarães
DOI: https://doi.org/10.1007/978-3-319-76834-2_8
2018-07-11
Abstract:This chapter co-authored by Jacqueline Soares, patent examiner at the Brazilian sanitary security institute and then at the INPI, and Eduardo Guilmaraes, a sociologist, describes a controversy over the patentability of polymorph molecules, involving a wide diversity of actors, from the chemists of the Oswaldo Cruz Foundation, the chemicals industry, the pharmaceuticals industry, the INPI, and the sanitary security institute, to the Interministerial Group on Intellectual Property (GIPI) and right up to Parliament. Some molecules are indeed able to exist in several crystalline forms, which can influence the molecule’s properties (bio-availability, stability, efficacy). To what extent can the process of obtaining polymorphs be patented? The Ministry of Health and the ANVISA patent examination division, wanting to limit the extension of the patentability of pharmaceutical molecules, were against patents on polymorphs. The patent office, wanting to encourage incremental innovations, was in favour of them. This highly technical subject has become a matter of public debate involving science, industry, the state and civil society.
What problem does this paper attempt to address?